Cantargia names Dr Ignacio Garcia-Ribas as new chief medical officer.

NORDIC BUSINESS REPORT-February 26, 2020-Cantargia names Dr Ignacio Garcia-Ribas as new chief medical officer

(C)2020 M2 COMMUNICATIONS http://www.m2.com

Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Tuesday the appointment of Dr Ignacio Garcia-Ribas as chief medical officer (CMO) of Cantargia, from 1 March 2020.

In his new role, Garcia-Ribas will be a member of the executive management and have a key role in the advancement of the company's antibody CAN04 in phase IIa clinical development for non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC).

Dr Garcia-Ribas, who is medical oncologist, brings over 15 years of experience in oncology early drug development in the pharma industry. Most of his research activities have been carried out in the US and in Japan.

Most recently, Dr Garcia-Ribas held the position of senior medical director at Takeda and acted as Global Clinical Lead across several phase I...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT